Locked nucleic acid aptamers.
The aptamer technology has been introduced in the early 1990s. With this technique ligands for organic dyes and proteins have been identified in many research field, providing various inhibitory molecules that allow functional interference in biological systems. Aptamers can therefore be employed for various applications ranging from diagnostic to therapeutic assay formats. Locked nucleic acid aptamers (LNA-Aps) are oligonucleotides containing one or more LNA nucleotide monomers with a bicyclic furanose unit locked in an RNA mimicking sugar conformation, evolved in vitro to bind target ligands with high affinity and specificity. LNA-Aps are attractive alternatives to antibody- and small-molecule-based therapeutics due to their stability, low toxicity and immunogenecity.
Barciszewski
Jan
J
Institute of Bioorganic Chemistry of the Polish Academy of Sciences, , Poznan, Poland.
Medgaard
Michael
M
Koch
Troels
T
Kurreck
Jens
J
Erdmann
Volker A
VA
D052157:Aptamers, Nucleotide / Q000138:chemical synthesis* / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D016325:HIV Long Terminal Repeat; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism; D009841:Oligonucleotides / Q000138:chemical synthesis* / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000138:chemical synthesis; D019063:Tenascin / Q000378:metabolism; D013917:Thrombin / Q000378:metabolism
D052157:Aptamers, Nucleotide; D016328:NF-kappa B; D009841:Oligonucleotides; D009943:Organophosphorus Compounds; D019063:Tenascin; C477371:locked nucleic acid; C434331:phosphoramidite; D013917:Thrombin